NEUROENDOCRINE TUMOR RESEARCH FOUNDATION (EIN 201945347) - Form 990 Financial Analysis & Trantor Score

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2004

Legal Domicile

Principal Officer

ELYSE GELLERMAN

Phone

6179461780

Tax Period

2024-01-01 to 2024-12-31

NEUROENDOCRINE TUMOR RESEARCH FOUNDATION, founded in 2004, is a community nonprofit in the Diseases & Disorders sector that reported $4.0M in total revenue in fiscal year 2024. Revenue surged 25% from the prior year, signaling strong growth momentum. Expenses of $3.8M left a modest 5% surplus.

Mission

TO FUND RESEARCH TO DISCOVER CURES & MORE EFFECTIVE TREATMENTS FOR NEUROENDOCRINE CANCERS. THE NETRF IS COMMITTED TO IMPROVING THE LIVES OF THOSE AFFECTED BY NEURENDOCRINE CANCER BY PROVIDING INFORMATION & EDUCATIONAL RESOURCES.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2024)

Revenue Breakdown

Contributions & Grants $3,111,689

Program Service Revenue $0

Investment Income $855,797

Other Revenue $26,171

TOTAL REVENUE $3,993,657

Expense Breakdown

Grants Paid $2,219,056

Salaries & Benefits $1,019,619

Fundraising Expenses $492,545

Program Expenses $2,992,472

Other Expenses $539,802

TOTAL EXPENSES $3,778,477

Year-over-Year Comparison

	2024	2023	Change
Revenue	$3,993,657	$3,196,257	+0.2%
Expenses	$3,778,477	$3,580,473	+0.1%
Net Income	$215,180	$-384,216	-1.6%

Key Indicators

✓ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

Volunteers

Governance Policies

✓ Conflict of Interest Policy

✓ Whistleblower Policy

✓ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$199,006

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
MARK LEWIS MD	DIRECTOR	4.00	Director	$0	$0	$0
JONATHAN SOROFF UNTIL 012024	DIRECTOR	4.00	Director	$0	$0	$0
JULIE SHAFFER MEBANE	VICE PRESIDENT	4.00	Officer Director	$0	$0	$0
LAURIE RAINS	DIRECTOR	4.00	Director	$0	$0	$0
ANTHONY DETRE	DIRECTOR	4.00	Director	$0	$0	$0
STEPHEN BLACKWOOD PHD	DIRECTOR	4.00	Director	$0	$0	$0
STEPHEN KAUFER	DIRECTOR	4.00	Director	$0	$0	$0
JOSH MAILMAN	TREASURER	4.00	Officer Director	$0	$0	$0
JOSEPH LI MD	DIRECTOR	4.00	Director	$0	$0	$0
BRENDAN FOLEY UNTIL 62024	SECRETARY	4.00	Officer Director	$0	$0	$0
TODD GILMAN	PRESIDENT	4.00	Officer Director	$0	$0	$0
SUZANNE LUDLOW	SECRETARY	4.00	Officer Director	$0	$0	$0
LAURIE LITTLEPAGE	DIRECTOR	4.00	Director	$0	$0	$0
CARRIE CAMINO AS OF 42024	DIRECTOR	4.00	Director	$0	$0	$0
ELYSE GELLERMAN	CHIEF EXECUTIVE OFFICER	40.00	Officer	$199,006	$0	$199,006
SUSAN HARRINGTON	CHIEF DEVELOPMENT OFFICER	40.00	Highest	$179,000	$491	$179,491
ANNA GREENE	DIRECTOR OF RESEARCH	40.00	Highest	$137,064	$0	$137,064
JESSICA THOMAS	DIRECTOR OF PATIENT EDUCATION	40.00	Highest	$112,109	$20,162	$132,271
CHRISTINA COFFEY UNTIL 072024	DIRECTOR OF COMMUNICATIONS	1.00	Highest	$107,547	$5,017	$112,564

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2025	No data	No data	No data	No data
2024	$3,993,657	$3,778,477	$21,377,613	$215,180
2023	$3,196,257	$3,580,473	$20,633,243	$-384,216
2022	$3,075,371	$3,490,037	$20,523,118	$-414,666
2021	$8,207,303	$5,440,887	$26,608,419	$2,766,416
2020	$4,650,373	$4,020,651	$23,779,492	$629,722
2019	$5,224,012	$5,992,524	$22,312,772	$-768,512

NEUROENDOCRINE TUMOR RESEARCH FOUNDATION